BOLD (Boundless Bio) Total Debt per Share: $2.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOLD Boundless Bio Inc BOLD
14 GF Score
Price $2.52
! 3 Warning Signs
View Full Analysis

What is Boundless Bio Total Debt per Share?

Boundless Bio BOLD +2.02% 14 Total Debt per Share is $2.16 as of Mar. 2026. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

$2.16 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Boundless Bio's Total Debt Per Share for the quarter that ended in Mar. 2026 was $2.16.

Boundless Bio Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Boundless Bio's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio Total Debt per Share Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
0.02 0.23 0.10 2.14 2.19

Boundless Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.18 2.21 2.22 2.19 2.16
BOLD
14GF Score
Boundless Bio Inc BOLD
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boundless Bio Total Debt per Share Calculation

Boundless Bio's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(45.87+3.17)/22.41
=2.19

Boundless Bio's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(45.00+3.28)/22.41
=2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $2.16 mean?
Boundless Bio (BOLD) has a Total Debt per Share of $2.16 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Boundless Bio and its competitors.
Is Boundless Bio's Total Debt per Share too high?
Boundless Bio's current Total Debt per Share is $2.16. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Total Debt per Share compare to INKT and FLNA?
Boundless Bio's Total Debt per Share of $2.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Boundless Bio and its competitors. Boundless Bio's current Total Debt per Share is $2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Total Debt per Share of $2.16. The current Total Debt per Share is $2.16. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Total Debt per Share is $2.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Boundless Bio Business Description

Address 10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score

Get the complete analysis for BOLD

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.52
Price